KRAS and lung adenocarcinoma: Three KRAS-mutant lung adenocarcinoma cell lines (NCI-H1373, NCI-H358, and NCI-H441) were evaluated for PD-L1 expression 24 h after treatment with the MEK inhibitor U0126.